Non Invasive Prenatal Testing of Down Syndrome

Overview

This is a randomized controlled trial in women at risk following combined prenatal screening for Down Syndrome. Women will be asked about their preferences between NIPT and routine prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between NIPT and standard invasive prenatal diagnosis.

Full Title of Study: “Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 7, 2016

Detailed Description

This is a randomized controlled trial in women at risk following combined prenatal screening for Down Syndrome. Women will be asked about their preferences between NIPT and routine prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between NIPT and standard invasive prenatal diagnosis. The general objectives are : – Promote the rapid and large implementation of Non Invasive Prenatal Testing (NIPT) for Down syndrome. – Improve the management of women at risk after combined first trimester screening and reduce the number of invasive procedures and induced miscarriages . – Evaluate NIPT medically (in reducing the rate of invasive sampling and related complications, diagnostic performance and feasibility and acceptability in routine practice) and based on cost-analysis in comparison with standard invasive prenatal diagnosis currently proposed . – Clarify the conditions of implementation and dissemination of NIPT in the overall organization of prenatal screening for trisomy 21 (and provide data to later adjust or not the combination of tests and thresholds). Promote the organization as networks of professionals involved in prenatal screening for trisomy 21 in order to allow the emergence of a national system of collection of outcomes to improve the quality of practices The main judgement criteria are: – Main: – Percentage of fetal loss in each group – Secondary: – Percentage of invasive tests in each group (amniocentesis or chorionic villus sampling ) – Diagnostic performance of NIPT , in particular false positive and negative – Percentage of results within 3 weeks and average time interval for results of NIPT – Percentage of inconclusive results of DPANI – Percentage of other anomalies discovered at invasive sampling – Percentage of invasive samples taken despite normal NIPT (either because of later ultrasound anomaly or for maternal reinsurance) – Association between maternal characteristics ( weight, height, parity , previous history , serum markers … ) and the results of NIPT – Cost analysis of NIPT in routine clinical practice The study will include 2450 high risk women in order to be powered enough to detect a 1% reduction of miscarriages in the group undergoing NIPT instead of routine invasive prenatal diagnosis.

Interventions

  • Procedure: Non Invasive Prenatal Testing
  • Procedure: Invasive Prenatal Testing

Arms, Groups and Cohorts

  • Experimental: Non Invasive Prenatal Testing
    • Blood sample
  • Active Comparator: Invasive Prenatal Testing
    • CVS or amniocentesis

Clinical Trial Outcome Measures

Primary Measures

  • Number or miscarriages
    • Time Frame: at birth

Secondary Measures

  • Number or invasive tests
    • Time Frame: at birth
  • false positive and negative rates of NIPT
    • Time Frame: At birth
  • Dedicated questionnaire for patients
    • Time Frame: day 5
  • Cost of invasive tests and NIPT in euros
    • Time Frame: at birth
    • measure in euros

Participating in This Clinical Trial

Inclusion Criteria

  • pregnant women over 18 – at risk for Down syndrome> 1/250 based on combined screening using ultrasound together with maternal serum markers and prior to fetal karyotyping – singleton pregnancy – pregnancy between 11SA et 18SA – willing a fetal karyotype Exclusion Criteria:

  • risk for Down syndrome< 1/250 or >1/5 – NT> 3 mm, PAPP-A or beta HCG <0.3 MoM or >5 MoM – multiple pregnancy , vanishing twin – morphological abnormalities at US – Kown chromosomal anomaly in parents – Patients not willing a fetal karyotype

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Laurent J Salomon, MD, PhD, Principal Investigator, Assistance Publique – Hôpitaux de Paris
    • Michel VEKEMANS, MD, PhD, Study Director, Assistance Publique – Hôpitaux de Paris

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.